We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Endo to acquire Paladin Labs

Endo to acquire Paladin Labs

November 6, 2013
CenterWatch Staff

Endo Health Solutions has reached a definitive agreement to acquire Paladin Labs, a Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion, of which approximately 98% will be paid in stock. The acquisition accelerates Endo's strategic transformation to a global specialty healthcare company and creates a platform for future growth in North America and internationally. Each share of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company (New Endo). At $77 per Paladin Labs share, the transaction represents a 20% premium to Paladin Labs' share price on Nov. 4.

"The transaction with Endo provides Paladin Labs shareholders an attractive current premium for their shares while allowing for ongoing participation in the upside potential of the combined company," said Jonathan Ross Goodman, chairman and founder of Paladin Labs. "We are confident our 17 years of consecutive record revenues will continue unabated under Endo's stewardship.”

New Endo will be led by Endo's current management team. Paladin Labs will be a separate operating company under New Endo and will continue to be led by Paladin Labs' current management team, maintaining its current headquarters in Montreal. Its Canadian operations will continue under the Paladin Labs name. Operational and tax synergies as a result of the transaction are expected to total at least $75 million after tax savings on an annual basis. The savings are not expected to materially impact Paladin Labs' Canadian operations, and it is Endo's intention to continue to expand Paladin Labs' presence in the Canadian market.

The transaction is expected to close in the first half of 2014, subject to certain conditions and approvals. Shareholders representing approximately 34% of Paladin Labs outstanding shares have agreed to vote in favor of the transaction. These shareholders have the right to terminate this voting agreement if Endo's volume-weighted average share price declines more than 24% during an agreed reference period. 

Global News Drug Sponsors

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing